Kingsview Wealth Management LLC Has $1.91 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Kingsview Wealth Management LLC decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 25,797 shares of the medical research company’s stock after selling 144 shares during the period. Kingsview Wealth Management LLC’s holdings in Edwards Lifesciences were worth $1,910,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Bowman & Co S.C. lifted its stake in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after acquiring an additional 148 shares during the period. Mount Yale Investment Advisors LLC grew its position in shares of Edwards Lifesciences by 1.9% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after buying an additional 162 shares during the period. JFS Wealth Advisors LLC raised its stake in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the last quarter. Seascape Capital Management lifted its holdings in Edwards Lifesciences by 0.5% in the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after buying an additional 174 shares during the period. Finally, Cooper Financial Group raised its position in shares of Edwards Lifesciences by 2.8% during the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after acquiring an additional 175 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,000 shares of company stock worth $547,430. 1.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on EW. The Goldman Sachs Group upped their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Robert W. Baird lowered their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a research note on Thursday, January 16th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Trading Up 1.0 %

NYSE:EW opened at $71.05 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market cap of $41.91 billion, a P/E ratio of 10.25, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The business has a 50 day moving average price of $72.45 and a two-hundred day moving average price of $69.18.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.